Literature DB >> 12227616

Developmental outcome, including setback, in young children with severe visual impairment.

Naomi Dale1, Patricia Sonksen.   

Abstract

This study retrospectively investigated the developmental perspective of 69 children (40 males, 29 females) with 'potentially simple' congenital disorders of the peripheral visual system: development was examined in the context of degree of visual impairment. Developmental and visual assessments were carried out at 10 to 16 months (Time 1) and 27 to 54 months of age (Time 2). Participants were grouped according to (1) visual status: profound visual impairment (PVI), severe visual impairment (SVI); (2) developmental status on the Reynell-Zinkin scales. A majority of the sample showed normal development on all subscales (62% Time 1, 57% Time 2). Those with PVI were more developmentally vulnerable than SVI with a greater incidence of (1) uneven developmental profile at Time 1 (48% PVI, 16% SVI); (2) global learning difficulties at Time 2 (37% PVI, 0% SVI); (3) delay on individual subscales at Time 2 (p<0.02 PVI versus SVI); (4) deceleration (verbal comprehension 74% PVI, 24% SVI, sensorimotor understanding 70% PVI, 27% SVI); and (5) severe developmental setback (33% PVI, 7% SVI). Risk factors of visual level, age, and sex for poor developmental outcome in infants with visual impairment were established.

Entities:  

Mesh:

Year:  2002        PMID: 12227616     DOI: 10.1017/s0012162201002651

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  18 in total

Review 1.  The development of vision between nature and nurture: clinical implications from visual neuroscience.

Authors:  Giulia Purpura; Francesca Tinelli
Journal:  Childs Nerv Syst       Date:  2020-03-05       Impact factor: 1.475

2.  Developmental Outcome in Infants with Cardiovascular Disease After Cardiopulmonary Resuscitation: A Pilot Study.

Authors:  Hannah Ferentzi; Constanze Pfitzer; Lisa-Maria Rosenthal; Felix Berger; Katharina R L Schmitt; Peter Kramer
Journal:  J Clin Psychol Med Settings       Date:  2019-12

Review 3.  LncRNAs in ocular neovascularizations.

Authors:  Yacouba Cissé; Lang Bai; Min-Ting Chen
Journal:  Int J Ophthalmol       Date:  2019-12-18       Impact factor: 1.779

Review 4.  Retinoblastoma and vision.

Authors:  Omar Warda; Zishan Naeem; Kelsey A Roelofs; Mandeep S Sagoo; M Ashwin Reddy
Journal:  Eye (Lond)       Date:  2022-01-05       Impact factor: 3.775

5.  Associations among co-occurring medical conditions and cognition, language, and behavior in Down syndrome.

Authors:  Emily K Schworer; Ameena Ahmed; Lori Hogenkamp; Shelby Moore; Anna J Esbensen
Journal:  Res Dev Disabil       Date:  2022-04-22

6.  Frontal EEG asymmetry and later behavior vulnerability in infants with congenital visual impairment.

Authors:  Michelle A O'Reilly; Joe Bathelt; Elena Sakkalou; Hanna Sakki; Alison Salt; Naomi J Dale; Michelle de Haan
Journal:  Clin Neurophysiol       Date:  2017-09-08       Impact factor: 3.708

7.  Multidisciplinary assessment of vision in children with neurological disability.

Authors:  Claire Lundy; Nan Hill; Clive Wolsley; Myrtle Shannon; Julie McClelland; Kathryn Saunders; Jonathan Jackson
Journal:  Ulster Med J       Date:  2011-01

8.  The Incidence of Binocular Visual Impairment and Blindness in Children with Bilateral Retinoblastoma.

Authors:  Andrew W Stacey; Bronagh Clarke; Christos Moraitis; Ido Didi Fabian; Vicki Smith; Mandeep S Sagoo; M Ashwin Reddy
Journal:  Ocul Oncol Pathol       Date:  2018-06-19

9.  Reporting on Australian childhood visual impairment: the first 10 years.

Authors:  Susan Silveira; Frank J Martin; Maree Flaherty; Heather C Russell
Journal:  Eye (Lond)       Date:  2021-06-30       Impact factor: 4.456

10.  Story discourse and use of mental state language between mothers and school-aged children with and without visual impairment.

Authors:  Valerija Tadić; Linda Pring; Naomi Dale
Journal:  Int J Lang Commun Disord       Date:  2013-09-09       Impact factor: 3.020

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.